Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
Journal
Journal of Thoracic Oncology
Journal Volume
9
Journal Issue
11
Pages
1720-1725
Date Issued
2014
Abstract
Introduction: The development of complex renal cysts after crizotinib treatment for non-small-cell lung cancer (NSCLC) is a reported side effect. However, its occurrence and characteristics have not been reported. Methods: Medical records and computed tomography images of crizotinib-treated patients in three prospective clinical trials were reviewed. The size and Bosniak category of the renal cysts before and after crizotinib treatment were determined. Patients' clinical characteristics, tumor stage, treatment response, renal function, and outcomes were analyzed. Results: During December 2010 to March 2013, we enrolled 32 patients who received crizotinib. There were 23 patients who had renal cysts before crizotinib. The median follow-up time was 493 days. Seven patients (22%, six with baseline renal cyst and one without baseline renal cyst) had significant renal cyst change. Four (13% of all) had new complex renal cysts. The median time from crizotinib treatment to first recognization of significant renal cyst change was 77 days. After stopping crizotinib, complex renal cysts regressed significantly. Patients with significant renal cyst change received more previous anticancer therapy (median, 5 lines versus 3 lines, p = 0.04) and received crizotinib for longer duration (median, 956 days versus 248 days, p = 0.007) compared with those without significant renal cyst change. Conclusions: Change of renal cysts after crizotinib treatment is not uncommon. Development of complex renal cysts reverses after stopping crizotinib. Copyright ? 2014 by the International Association for the Study of Lung Cancer.
SDGs
Other Subjects
alectinib; anaplastic lymphoma kinase; creatinine; crizotinib; anaplastic lymphoma kinase; crizotinib; protein tyrosine kinase; pyrazole derivative; pyridine derivative; adult; advanced cancer; aged; Article; bone metastasis; cancer staging; cancer survival; clinical article; clinical feature; clinical trial (topic); computer assisted tomography; creatinine blood level; female; follow up; human; kidney cyst; kidney function; lung adenocarcinoma; male; medical record review; middle aged; non small cell lung cancer; outcome assessment; priority journal; progression free survival; prospective study; psoas muscle; treatment response; tumor volume; Carcinoma, Non-Small-Cell Lung; chemically induced; drug effects; enzymology; kidney; kidney polycystic disease; Lung Neoplasms; metabolism; pathology; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kidney; Kidney Diseases, Cystic; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases
Publisher
Lippincott Williams and Wilkins
Type
journal article